- Home
- MIST vs INM Comparison
MIST vs INM Comparison
Compare MIST & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIST
- INM
- Stock Information
- Founded
- MIST 2003
- INM 1981
- Country
- MIST Canada
- INM Canada
- Employees
- MIST N/A
- INM N/A
- Industry
- MIST Biotechnology: Pharmaceutical Preparations
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- MIST Health Care
- INM Health Care
- Exchange
- MIST Nasdaq
- INM Nasdaq
- Market Cap
- MIST 164.9M
- INM 5.0M
- IPO Year
- MIST N/A
- INM N/A
- Fundamental
- Price
- MIST $1.87
- INM $2.07
- Analyst Decision
- MIST Strong Buy
- INM
- Analyst Count
- MIST 3
- INM 0
- Target Price
- MIST $6.33
- INM N/A
- AVG Volume (30 Days)
- MIST 1.5M
- INM 116.2K
- Earning Date
- MIST 11-11-2025
- INM 11-13-2025
- Dividend Yield
- MIST N/A
- INM N/A
- EPS Growth
- MIST N/A
- INM N/A
- EPS
- MIST N/A
- INM N/A
- Revenue
- MIST N/A
- INM $4,942,633.00
- Revenue This Year
- MIST N/A
- INM N/A
- Revenue Next Year
- MIST N/A
- INM N/A
- P/E Ratio
- MIST N/A
- INM N/A
- Revenue Growth
- MIST N/A
- INM 7.50
- 52 Week Low
- MIST $0.63
- INM $1.72
- 52 Week High
- MIST $2.75
- INM $8.27
- Technical
- Relative Strength Index (RSI)
- MIST 43.30
- INM 42.37
- Support Level
- MIST $1.85
- INM $2.04
- Resistance Level
- MIST $2.14
- INM $2.26
- Average True Range (ATR)
- MIST 0.11
- INM 0.14
- MACD
- MIST -0.03
- INM -0.01
- Stochastic Oscillator
- MIST 5.69
- INM 10.44
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.